Literature DB >> 21462123

[Mutation analysis of phenylalanine hydroxylase gene in patients w ith phenylketonuria in Henan province].

Hong-jun GUO1, Zhen-hua ZHAO, Miao JIANG, Hui-rong SHI, Xiang-dong KONG.   

Abstract

OBJECTIVE: To study the characteristics of the phenylalanine hydroxylase gene (PAH) mutations in patients with phenylketonuria (PKU) in Henan province, in order to provide basic information for genetic counseling and prenatal diagnosis.
METHODS: Mutations of the PAH gene were detected in exons 1-13 with flanking introns of PAH gene by PCR and DNA sequencing in 47 families with PKU.
RESULTS: A total of 25 different mutations were detected in 83 out of 94 PAH alleles (88.3%). Among them, E79fX13, H271R and D415Y have not been reported previously. It was the first time that IVS10-14C to G mutation was reported in Chinese PKU population. The mutations p.R243Q, EX6-96A to G, p.Y356X, IVS401G to A, p.R111X, p.V399V and p.R413P, were the prevalent mutations with relative frequencies of 20.5%, 12.0%, 9.6%, 9.6%, 8.4%, 8.4% and 7.2% respectively.
CONCLUSION: The mutations of the PAH gene in patients with classical phenylketonuria in Henan province were similar to that in other areas of China. Prenatal gene diagnosis for PKU by PAH gene sequencing is efficient for most PKU families.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21462123     DOI: 10.3760/cma.j.issn.1003-9406.2011.02.005

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  2 in total

1.  Mutation spectrum of PAH gene in phenylketonuria patients in Northwest China: identification of twenty novel variants.

Authors:  Yousheng Yan; Chuan Zhang; Xiaohua Jin; Qinhua Zhang; Lei Zheng; Xuan Feng; Shengju Hao; Huafang Gao; Xu Ma
Journal:  Metab Brain Dis       Date:  2019-02-12       Impact factor: 3.584

2.  Genotypes of 2579 patients with phenylketonuria reveal a high rate of BH4 non-responders in Russia.

Authors:  Polina Gundorova; Anna A Stepanova; Irina A Kuznetsova; Sergey I Kutsev; Aleksander V Polyakov
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.